$0.870
-0.029 (-3.33%)Zum Schluss
RDHL-News
RDHL-Events
RedHill Biopharma Acquires Exclusive Global Commercialization Rights to Rebyota and Clenpiq
RedHill Biopharma announced the transformational acquisition of exclusive global and U.S. commercialization rights to Rebyota and Clenpiq, from Ferring Pharmaceuticals, as part of Ferring's ongoing strategic refocusing. Dror Ben-Asher, RedHill's Chief Executive Officer, said: "We have executed a clear strategic sequence. We have monetized Talicia for $18M cash upfront, plus $35 million in potential upside, used $12M to secure commercialization rights to two established, proprietary, FDA-approved gastrointestinal drugs, that collectively generated approximately $37.5M in U.S. net sales in 2025, and emerged with a materially larger, fully controlled commercial business and a stronger liquidity position. Rebyota and Clenpiq are expected to generate a positive cash contribution to RedHill. This, combined with RedHill's experienced and lean commercial team and proven development capabilities, creates a scalable foundation for further growth, including additional acquisition of complementary revenue-generating products." Under the terms of the agreement, RedHill obtained an exclusive global commercialization license of Rebyota and an exclusive U.S. commercialization license of Clenpiq, for an upfront payment to Ferring of $12M, plus tiered royalties on net sales and potential milestones. Ferring retains its Rebyota manufacturing facilities, and Ferring will continue to supply Rebyota through the term of the agreement.
RedHill Biopharma Acquires Global Commercialization Rights to Rebyota and Clenpiq
RedHill Biopharma announced the acquisition of exclusive global and U.S. commercialization rights to Rebyota and Clenpiq, from Ferring Pharmaceuticals, as part of Ferring's ongoing strategic refocusing. Under the terms of the agreement, RedHill obtained an exclusive global commercialization license of Rebyota and an exclusive U.S. commercialization license of Clenpiq, for an upfront payment to Ferring of $12M, plus tiered royalties on net sales and potential milestones. Ferring retains its Rebyota manufacturing facilities, and Ferring will continue to supply Rebyota through the term of the agreement.
RedHill Biopharma Sells Talicia Business for $18M
RedHill Biopharma announced the divestment of its Talicia business to a subsidiary of Apotex Health for an upfront payment of $18M plus up to an additional $35M in potential payments based on worldwide net sales milestones. Under the terms of the agreement, RedHill received $18M in cash and has the potential to receive up to an additional $35M in payments based on worldwide net sales milestones from Apotex. In return, Apotex will receive RedHill's 70% interest in Talicia, following Apotex's prior acquisition of Cumberland Pharmaceuticals Inc.'s U.S. branded business, which included Cumberland Pharmaceuticals Inc.'s 30% ownership in Talicia.
RedHill Biopharma Completes Private Placement of 8.57 Million ADS
RedHill Biopharma announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 8,571,429 American Depositary Shares, each ADS representing ten thousand ordinary shares of the company, series A-1 warrants to purchase up to an aggregate of 8,571,429 ADSs and series A-2 warrants to purchase up to an aggregate of 8,571,429 ADSs, at a combined purchase price of 70c per ADS and accompanying warrants in a private placement. The Series A-1 warrants have an exercise price of $0.86 per ADS, are exercisable immediately and have a term of five years following the Effectiveness Date, and the Series A-2 warrants have an exercise price of 70c per ADS, are exercisable immediately and have a term of 18 months following the Effectiveness Date. The private placement is expected to close on June 22, subject to the satisfaction of customary closing conditions. The gross proceeds to the company from this offering are expected to be approximately $6M, before deducting the placement agent's fees and other offering expenses payable by the company. The potential additional gross proceeds to the company from the series A-1 warrants and the series A-2 warrants, if fully exercised on a cash basis, will be approximately $13.4M. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
RedHill Biopharma Advances Opaganib Collaborations for EVD
RedHill Biopharma is actively discussing potential collaborations for advancement of its investigational oral drug, opaganib, to combat Ebola virus disease or EVD, which can be fatal in approximately half of all cases, including the WHO's SOLIDARITY CORE clinical trial platform and pharma collaborations. Opaganib is an orally administered, host-directed, small molecule SPHK2 inhibitor with demonstrated antiviral properties in advanced clinical stage. Peer-reviewed published data shows opaganib's host-direction action stems from its ability to inhibit replication of viruses like SARS-CoV-2 and Ebola. In EVD specifically, opaganib offers a potential dual mechanism of action; blocking the PI3K/Akt pathway critical for filovirus entry and suppressing NLRP3 inflammasome and reducing IL-6/TNFalpha and S1P-mediated vascular permeability. The company has provided information to relevant government, industry and other organizations, regarding supply readiness and all available clinical and preclinical safety and efficacy data to aid rapid clinical and regulatory discussions. Opaganib is in development for multiple oncology, viral, inflammatory and diabetes and obesity-related indications. Opaganib is an investigational new drug. It has not been approved by any regulatory authority and is not available for commercial distribution. Inclusion in the WHO CORE platform cannot be guaranteed.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.